📅 PUBMED DAILY TRIAGE — 2026-04-24
Window: 2026-04-23T09:00:00Z → 2026-04-24T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~95 candidates | Candidates fully evaluated: 16 High priority: 3 | Standard: 10 | Low/archive: 3 | Unsolicited finds: 0 Run status: SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Early Cancer Detection (liquid biopsy, ctDNA, cfDNA)
TR-2026-04-24-001 / PMID 42024827 · Canine Olfaction + Bayesian Modeling for Multicancer Detection From Breath · 9/10 → Phase II multicenter study (n=1,502) in India: 90.8% sensitivity, 91.3% specificity, AUC 0.962 across 7 cancer types; stage I-II sensitivity 90.6% — a novel, ultra-low-cost early-detection triage approach for LMICs. J Clin Oncol.
TR-2026-04-24-002 / PMID 42025761 · COCA: Colorectal Cancer Detection via Non-Contrast CT + Deep Learning · 8/10 → Multicenter international validation (n=2,053) plus 2 real-world consecutive-patient cohorts (n=27,433): AUC 0.967–0.996, 88.2–86.6% real-world sensitivity, 99.5–99.8% specificity; improved radiologist sensitivity by 20.4%. Ann Oncol.
Hematologic Malignancies
TR-2026-04-24-003 / PMID 42026180 · ASC4OPT: Asciminib Dose Optimization in CML-CP After ≥2 TKIs · 8/10 → Phase 3b study (NCT04948333, n=169): MMR rate 39.4% at Week 48, 43.6% at Week 96; dose escalation to 200mg QD achieves 17.5% additional MMR; supports asciminib as standard of care in 3rd-line+ CML-CP. Leukemia.
🟢⚪ STANDARD (5–7) — Top by Topic
Cardiovascular-Metabolic: GLP-1/SGLT2
- TR-2026-04-24-004 / PMID 42026662 · Generic semaglutide non-inferior to innovator, Phase 3 RCT, India, n=320, HbA1c −2.20% · 7/10 · Treatment Innovation
- TR-2026-04-24-011 / PMID 42026424 · Sequential intragastric balloon → GLP-1 RA superior 12-month weight loss · 5/10 · Treatment Innovation
Rare Diseases with High Unmet Need
- TR-2026-04-24-005 / PMID 42026640 · Couple-based comprehensive carrier screening, 15 centers China, rare + common genetic disorders · 7/10 · Genomics/Precision Medicine
- TR-2026-04-24-009 / PMID 42026675 · Costello syndrome muscle US: 100% fibroadipose infiltration, HRAS metabolic mechanism · 5/10 · Diagnostics
- TR-2026-04-24-013 / PMID 42026676 · Adult NF1 cancer center clinic, first 100 patients descriptive · 5/10 · Other/Underserved Population
AI/ML in Clinical Diagnostics and Imaging
- TR-2026-04-24-006 / PMID 42026134 · ML competing-risk models for brain met prediction in breast/lung cancer; C-index 0.95/0.88 · 6/10 · Diagnostics
- TR-2026-04-24-012 / PMID 42026673 · SHAP delta-radiomics across 7 RT weeks for xerostomia prediction in HN cancer · 5/10 · Diagnostics
Novel Therapeutics: Immunotherapy / Targeted Therapy
- TR-2026-04-24-008 / PMID 42026573 · Camrelizumab + apatinib Phase 2 in ICI-naive metastatic RCC after TKI failure; mPFS 11.6m, ORR 41.5% · 6/10 · Treatment Innovation
Hematologic Malignancies
- TR-2026-04-24-007 / PMID 42026320 · Venetoclax off-label pediatric malignancies: FAERS pharmacovigilance signals for neutropenia/infection · 6/10 · Drug Development
Early Cancer Detection (liquid biopsy)
- TR-2026-04-24-010 / PMID 42025056 · Integrated single-tube EV miRNA detection via CRISPR/Cas12a + multivalent aptamer DNA scaffold; AUC 0.85 (MUC1+ EVs) · 5/10 · Diagnostics/Early Detection (in vitro)
💡 UNSOLICITED FINDS
None identified. Sentinel scan top 10 results fully overlapped with watchlist topic searches.
📊 TODAY'S BREAKDOWN
By research category:
- Early Detection: 3 (001, 002, 010)
- Treatment Innovation: 4 (003, 004, 008, 011)
- Diagnostics: 5 (006, 009, 010, 012, 013)
- Genomics/Precision Medicine: 1 (005)
- Drug Development: 2 (007, 015)
- Other: 1 (013)
By evidence maturity:
- Potentially Practice-Changing: 1 (PMID 42026180)
- Validated: 2 (PMID 42024827, 42025761, 42026662)
- Exploratory: 12
By watchlist topic (reviewed / kept / highest score):
| Topic | Raw | Reviewed | Kept | High Score |
|---|---|---|---|---|
| Hematologic malignancies | 83 | 10 | 2 | 8 |
| CBC/ML hematology | 1 | 1 | 0 | 3 |
| Early cancer detection | 38 | 10 | 4 | 9 |
| AI/ML diagnostics | 94 | 10 | 2 | 8 |
| Precision oncology | 115 | 5 | 1 | 8 |
| Novel therapeutics | 338 | 10 | 1 | 6 |
| GLP-1/SGLT2 cardiometabolic | 69 | 10 | 2 | 7 |
| Aging/longevity | 162 | 5 | 0 | N/A |
| Rare diseases | 121 | 10 | 3 | 7 |
| Sentinel | 104 | 10 | 0 | N/A |
By source type: peer_reviewed: 15 | preprint: 0
Topics with zero 8+ articles this run:
- CBC-based diagnostics and ML in hematology (sparse: 1 raw result)
- Novel therapeutics: immunotherapy/CAR-T/targeted therapy
- Cardiovascular-metabolic: GLP-1/SGLT2
- Aging, longevity, and population health
- Rare diseases with high unmet need
- Sentinel scan
🔧 RUN NOTES
- No window expansion triggered: 16 articles classified across all topics; threshold of 5 relevant records met.
- Truncation logged: Novel therapeutics returned 338 raw results; precision oncology 115; aging/longevity 162; all capped at 10 for abstract review. Top results from each topic batch were reviewed.
- Aging/longevity abstracts not retrieved: API batch response truncated before returning abstracts for 42026604, 42026557, 42026360, 42026253, 42026226. Zero articles from this topic in final output. Topic flagged for closer review if sparsity persists.
- CBC topic sparse: Only 1 result (PMID 42023444); abstract not retrieved. Deferred to 2026-04-25 run.
- Sentinel overlap: All 10 sentinel scan results already captured via watchlist topic searches; zero unsolicited finds.
- Prior state deduplication: All 16 final PMIDs confirmed new against state.json fingerprint list (last run: 2026-04-23).
- Rolling 7-day zero-HIGH topics: Aging/longevity and CBC/ML hematology have now had zero 8+ articles for multiple consecutive runs. Consider query broadening next week.
- 3 HIGH priority alerts sent to Telegram (limit 5; 3 HIGH articles this run).
- PMID 42023444 deferred to next run for abstract retrieval retry.